2020 Obsessive Compulsive Disorder (OCD) Drug Pipeline Report- Current Status, Phase, Mechanism, Route of Administration, and Companies, of Pre-Clinical And Clinical Drugs

The 2020 Obsessive Compulsive Disorder (OCD) pipeline report presents a comprehensive overview of the research and development of Obsessive Compulsive Disorder (OCD) drug candidates. It presents drugs in development that could potentially reach the market in the next 5 to 10 years: One drug in Research phase, four drugs in Pre-clinical phase, one drug in Phase 1, one drugs in Phase 2 and one drug in Phase 3.

As of February 2020, the Obsessive Compulsive Disorder (OCD) pipeline remains robust with 8 therapeutic candidates under development. An increasing number of companies are actively participating in the development of Obsessive Compulsive Disorder (OCD) treatment. Diverse types of targeted therapies are being explored through clinical trials including CB1 and CB2 receptor agonist; Glutamate modulator; Metabotropic glutamate receptor 4 agonist; NMDA receptor antagonist; PDE7 inhibitor.

The report provides complete details of pipeline drugs including the development phase, mechanism of action, companies involved, clinical trial developments, molecule type, and other details. Further, the report also provides Obsessive Compulsive Disorder (OCD) drug development history, latest news, and other developments.

It assists companies, governments, investors and research organizations to understand the current status in 2020 and possible development in the next 10 years. Further, it enables readers to track new companies in the market and their developments. The product portfolio of different companies and their growth strategies are also detailed in the report.

Publisher Expertise

The publisher's online databases analyze pipeline drugs and developments for over 2,000 diseases worldwide. All our reports and databases are developed through intensive primary and secondary research methods. The insights and data presented in the databases are validated through industry experts and represent completely unbiased opinions.

Scope:

• The report scope comprises of both pre-clinical phase and clinical phase development drugs for Obsessive Compulsive Disorder (OCD) development
• Obsessive Compulsive Disorder (OCD) pipeline compounds and molecules under study by both large scale and small companies are included in the report
• Obsessive Compulsive Disorder (OCD) pipeline across different phases including discovery, research, and pre-clinical stage, phase 1, phase 2, phase 3 and pre-registration phases are covered
• Drug profile comprising of current development status, regulatory progress, companies, sponsors, mechanism of action, route of administration, molecule, and discovery details are covered
• Further, orphan drug status, fast track designation, different grants awarded and special status for Obsessive Compulsive Disorder (OCD) pipeline candidates included
• Business overview and snapshot of all companies involved in Obsessive Compulsive Disorder (OCD) pipeline are included
• Latest market and pipeline developments are provided in the report

Obsessive-Compulsive Disorder pipeline companies included in the report are: Addex Therapeutics Ltd, Amorsa Therapeutics Inc, Biogen Inc, Biohaven Pharmaceutical Holding Company Ltd, Cannabis Science Inc, Omeros Corp, Phytecs, Seropeutics LLC.

Obsessive-Compulsive Disorder pipeline drugs profiled in the report include: ADX88178, NMDA Receptor for Obsessive Compulsive Disorder, rituximab, troriluzole (BHV-4157), CBIS-OCD-001, OMS527, PECS-101, SERx-480.